Looks like this quarter sees the company restructure complete including product repositioning with the ground prepared for FY23. Regulatory approvals received or to be received in this quarter look promising as well as the cost cutting which appears needed given the burn through of the cash balance. Hopefully start to see the turnaround being reflected in FY23 reporting. IMO.
